We revisit the many eras of DLBCL care, from a time before the availability of rituximab and PET scans to how it is being treated today.
Among the many lines of research surrounding DLBCL, researchers are investigating whether chronotherapy can impact clinical outcomes.
Researchers described the case study of a patient planned for orthopedic surgery who was incidentally discovered to have DLBCL.
The need for therapeutic options capable of providing durable remission and long-term survival for patients with high-risk DLBCL has staggered.
About a quarter of patients with diffuse large B-cell lymphoma (DLBCL) present with limited stage (LS-DLBCL). LS-DLBCL is usually defined as Ann Arbor stages 1 to 2 disease (tumor is restricted to above or below the diaphragm) with largest mass size < 10 cm in diameter. However, no standard definition exists. According to Rojek and…
The R-CHOP regimen (consisting of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone) has revolutionized the treatment of diffuse large B-cell lymphoma (DLBCL). Improvements in patient outcomes have become widely known, with long-term disease-free survival rates increasing to 60%-70%. However, some patients (up to 40%) develop relapsed or refractory disease (rrDLBCL), which has a poor prognosis.…
Staging diffuse large B-cell lymphoma and monitoring treatment response are 2 ways to predict the prognosis of patients with the disease.
Here we present recommendations for palliative radiotherapy in DLBCL as suggested by Wright et al in Clinical Lymphoma, Myeloma and Leukemia.